Short Interest in Axon Enterprise, Inc. (NASDAQ:AXON) Increases By 14.7%

Axon Enterprise, Inc. (NASDAQ:AXON) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 2,570,000 shares, a growth of 14.7% from the December 15th total of 2,240,000 shares. Based on an average trading volume of 883,200 shares, the short-interest ratio is presently 2.9 days.

Insider Buying and Selling

In other news, Director Caitlin Elizabeth Kalinowski sold 450 shares of Axon Enterprise stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total transaction of $271,831.50. Following the transaction, the director now owns 6,929 shares in the company, valued at approximately $4,185,601.03. The trade was a 6.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Joshua Isner sold 20,000 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $606.15, for a total value of $12,123,000.00. Following the completion of the sale, the president now owns 208,166 shares of the company’s stock, valued at $126,179,820.90. The trade was a 8.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,545 shares of company stock worth $30,721,337 in the last 90 days. Insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Quent Capital LLC raised its holdings in shares of Axon Enterprise by 1,875.0% in the 3rd quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 75 shares during the last quarter. Prestige Wealth Management Group LLC raised its stake in shares of Axon Enterprise by 115.8% in the third quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 44 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of Axon Enterprise by 4,750.0% in the fourth quarter. Versant Capital Management Inc now owns 97 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 95 shares in the last quarter. Brooklyn Investment Group purchased a new position in shares of Axon Enterprise during the third quarter valued at approximately $41,000. Finally, Planning Capital Management Corp grew its holdings in Axon Enterprise by 83.3% during the third quarter. Planning Capital Management Corp now owns 121 shares of the biotechnology company’s stock worth $48,000 after buying an additional 55 shares in the last quarter. 79.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

AXON has been the subject of a number of recent analyst reports. Northland Securities increased their target price on shares of Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research report on Monday, November 11th. TD Cowen began coverage on shares of Axon Enterprise in a research note on Wednesday, January 8th. They set a “buy” rating and a $700.00 target price for the company. Robert W. Baird upped their price target on shares of Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a research report on Friday, December 6th. JMP Securities lifted their price objective on Axon Enterprise from $430.00 to $500.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 31st. Finally, The Goldman Sachs Group upped their target price on Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $504.92.

Axon Enterprise Stock Up 1.4 %

Shares of AXON traded up $8.05 during trading hours on Friday, reaching $593.89. The stock had a trading volume of 533,566 shares, compared to its average volume of 1,040,913. The firm has a 50-day simple moving average of $617.37 and a 200 day simple moving average of $458.84. Axon Enterprise has a 12 month low of $247.04 and a 12 month high of $698.67. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $45.28 billion, a price-to-earnings ratio of 153.46, a P/E/G ratio of 5.71 and a beta of 1.04.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.